Literature DB >> 32215182

A Radiation Oncologist's Guide to Axillary Management in Breast Cancer: A Walk Through the Trials.

Julie K Jang1, Elana R Sverdlik2, Naomi R Schechter1.   

Abstract

PURPOSE OF REVIEW: The axilla is the most common site for breast cancer nodal metastases. Aggressive management includes axillary lymph node dissection (ALND), radiotherapy, and systemic therapy, but carries the risks of lymphedema and "overtreatment". We review the clinical trials that led to de-escalation of axillary management and their nuances that are often overlooked. RECENT
FINDINGS: With the rise of sentinel lymph node biopsy, several trials conclude that ALND can be omitted in specific populations. However, the subtleties in those trials, such as the role of chemotherapy and radiotherapy, have yet to be clarified. These discussions carry forward into the era of neoadjuvant chemotherapy, where ongoing trials investigate who needs ALND and/or radiation.
SUMMARY: This review examines the clinical trials that form the standard of care, and highlights why axillary management is individualized today.

Entities:  

Keywords:  axilla; axillary lymph node dissection; breast cancer; lymph node metastasis; radiotherapy; sentinel lymph node biopsy

Year:  2019        PMID: 32215182      PMCID: PMC7093898          DOI: 10.1007/s12609-019-00330-6

Source DB:  PubMed          Journal:  Curr Breast Cancer Rep        ISSN: 1943-4588


  87 in total

1.  POSNOC: A Randomised Trial Looking at Axillary Treatment in Women with One or Two Sentinel Nodes with Macrometastases.

Authors:  A Goyal; D Dodwell
Journal:  Clin Oncol (R Coll Radiol)       Date:  2015-08-05       Impact factor: 4.126

Review 2.  Individualization of post-mastectomy radiotherapy and regional nodal irradiation based on treatment response after neoadjuvant chemotherapy for breast cancer : A systematic review.

Authors:  David Krug; René Baumann; Wilfried Budach; Jürgen Dunst; Petra Feyer; Rainer Fietkau; Wulf Haase; Wolfgang Harms; Thomas Hehr; Marc D Piroth; Felix Sedlmayer; Rainer Souchon; Frederik Wenz; Rolf Sauer
Journal:  Strahlenther Onkol       Date:  2018-01-30       Impact factor: 3.621

3.  Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902.

Authors:  Johanna G H van Nes; Hein Putter; Jean-Pierre Julien; Michelle Tubiana-Hulin; Marc van de Vijver; Jan Bogaerts; Monika de Vos; Cornelis J H van de Velde
Journal:  Breast Cancer Res Treat       Date:  2008-05-18       Impact factor: 4.872

4.  Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.

Authors:  Judy C Boughey; Vera J Suman; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Bret Taback; A Marilyn Leitch; Henry M Kuerer; Monet Bowling; Teresa S Flippo-Morton; David R Byrd; David W Ollila; Thomas B Julian; Sarah A McLaughlin; Linda McCall; W Fraser Symmans; Huong T Le-Petross; Bruce G Haffty; Thomas A Buchholz; Heidi Nelson; Kelly K Hunt
Journal:  JAMA       Date:  2013-10-09       Impact factor: 56.272

5.  Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

Authors:  Joseph A Sparano; Robert J Gray; Della F Makower; Kathleen I Pritchard; Kathy S Albain; Daniel F Hayes; Charles E Geyer; Elizabeth C Dees; Matthew P Goetz; John A Olson; Tracy Lively; Sunil S Badve; Thomas J Saphner; Lynne I Wagner; Timothy J Whelan; Matthew J Ellis; Soonmyung Paik; William C Wood; Peter M Ravdin; Maccon M Keane; Henry L Gomez Moreno; Pavan S Reddy; Timothy F Goggins; Ingrid A Mayer; Adam M Brufsky; Deborah L Toppmeyer; Virginia G Kaklamani; Jeffrey L Berenberg; Jeffrey Abrams; George W Sledge
Journal:  N Engl J Med       Date:  2018-06-03       Impact factor: 91.245

6.  Does axillary boost increase lymphedema compared with supraclavicular radiation alone after breast conservation?

Authors:  Shelly B Hayes; Gary M Freedman; Tianyu Li; Penny R Anderson; Eric Ross
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-12-01       Impact factor: 7.038

7.  Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

Authors:  Priya Rastogi; Stewart J Anderson; Harry D Bear; Charles E Geyer; Morton S Kahlenberg; André Robidoux; Richard G Margolese; James L Hoehn; Victor G Vogel; Shaker R Dakhil; Deimante Tamkus; Karen M King; Eduardo R Pajon; Mary Johanna Wright; Jean Robert; Soonmyung Paik; Eleftherios P Mamounas; Norman Wolmark
Journal:  J Clin Oncol       Date:  2008-02-10       Impact factor: 44.544

Review 8.  Axillary Nodal Management Following Neoadjuvant Chemotherapy: A Review.

Authors:  Melissa Pilewskie; Monica Morrow
Journal:  JAMA Oncol       Date:  2017-04-01       Impact factor: 31.777

9.  Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.

Authors:  Amila Orucevic; Robert E Heidel; John L Bell
Journal:  Breast Cancer Res Treat       Date:  2016-05-20       Impact factor: 4.872

10.  Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.

Authors:  P McGale; C Taylor; C Correa; D Cutter; F Duane; M Ewertz; R Gray; G Mannu; R Peto; T Whelan; Y Wang; Z Wang; S Darby
Journal:  Lancet       Date:  2014-03-19       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.